Siwa Therapeutics
  • Home
  • Leadership
  • Science
    • Senescence
    • Diseases
  • Data
    • SIWA 318
    • Data
    • Other Products
  • Media
    • News
    • Videos
  • Partners
  • Contact

Month: January 2018

Home / 2018 / January
09Jan 2018 by siwa-admin-2017

Third Annual Healthspan Extension Policy and Regulation Workshop

Events
- Upcoming
Read More

Recent Posts

  • In The News: 1000 Longevity Leaders
  • BIO Digital 2020
  • In The News: SIWA Joins the fight against COVID-19
  • In the News: SIWA Featured on Chicago Business Journal
  • In the News: SIWA Therapeutics Joins the Ranks of SpaceX, Apple & Google with Our Inclusion in MIT Technology Reviews Top 10 Breakthrough Technologies of 2020.

Archives

  • June 2020
  • May 2020
  • March 2020
  • February 2020
  • September 2019
  • March 2019
  • April 2018
  • January 2018
  • June 2017
  • May 2017
  • October 2016

Categories

  • Events
  • In The News
  • News
  • Press Releases

About Us

SIWA Therapeutics, Inc. is a pre-clinical stage company with a first-in-class humanized monoclonal antibody, SIWA 318H, that selectively targets both senescent cells and cancer cells.

Recent News

  • In The News: 1000 Longevity Leaders
  • BIO Digital 2020
  • In The News: SIWA Joins the fight against COVID-19

JOIN OUR MAILING LIST

Navigation

  • Home
  • Leadership
  • Science
    • Senescence
    • Diseases
  • Data
    • SIWA 318
    • Data
    • Other Products
  • Media
    • News
    • Videos
  • Partners
  • Contact